Hassan Issa, MD
Medical Oncology · Wilmington, OHNPI 1720278708
Payments from drug & device makers
Across 138 payments — averaging $32.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tosoh Bioscience, Inc.$2K
- Johnson & Johnson$477
- Regeneron Healthcare Solutions, Inc.$290
- Novartis$242
- Amgen$188
- AstraZeneca$140
- plus $2K from 32 others
What the payments were for
- Food & beverage$2,72560%
- Education$1513%
- Gifts$1,63236%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tosoh Bioscience, Inc. | 3 | $1,632 |
| Johnson & Johnson(2 entities) | 17 | $477 |
| Regeneron Healthcare Solutions, Inc. | 11 | $290 |
| Novartis | 13 | $242 |
| Amgen | 10 | $188 |
| AstraZeneca | 5 | $140 |
| Incyte Corporation | 7 | $131 |
| E.r. Squibb & Sons, L.L.C. | 8 | $125 |
| Sanofi | 5 | $122 |
| Daiichi Sankyo Inc. | 6 | $119 |
| Pfizer | 6 | $101 |
| Stemline Therapeutics Inc. | 5 | $93 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $85 |
| Tempus AI, Inc | 3 | $77 |
| Genmab U.S., Inc. | 3 | $73 |
| Lilly USA, LLC | 4 | $70 |
| Merck | 2 | $54 |
| Kyowa Kirin, Inc. | 3 | $49 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Tersera Therapeutics LLC | 1 | $39 |
| Genentech USA, Inc. | 2 | $34 |
| Foundation Medicine, Inc. | 1 | $33 |
| Bristol Myers Squibb | 2 | $33 |
| Gilead(2 entities) | 2 | $27 |
| Morphosys, US Inc. | 1 | $24 |
| GSK | 1 | $20 |
| Progenics Pharmaceuticals, Inc. | 1 | $20 |
| Bayer | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Verastem, Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Adaptive Biotechnologies Corporation | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Siemens Medical Solutions USA, Inc. | 1 | $16 |
| AbbVie | 1 | $15 |
| Blueprint Medicines Corporation | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CORT, ST AIA-PACK$1,088
- CORTISOL, AIA-PACK Sample Diluting Sol$1,088
- ACTH, ST AIA-PACK$1,088
- NOZZLE ASSY, 360$544
- CORTISOL, AIA-PACK Calibrator Set$544
- ACTH, AIA-PACK CALIBRATOR SET$544
- ACTH, ST AIA-PACK SDS$544
- Wash Concentrate, AIA-PACK$544
- Erleada$125
- LIBTAYO$116
How this compares
$4,508 in reported general payments places this provider in the 30th percentile of 157 medical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 12 | $185,708 |
| Abiraterone Acetate | 47 | $79,778 |
| EliquisApixaban | 60 | $38,371 |
| XareltoRivaroxaban | 13 | $15,090 |
| Anastrozole | 73 | $840 |
| Letrozole | 42 | $744 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 44 | $615 |
| Dexamethasone | 51 | $514 |
| Prednisone | 130 | $407 |
| Prochlorperazine Maleate | 25 | $356 |
| Potassium Chloride | 15 | $356 |
| Oxycodone Hcl | 17 | $309 |
| Gabapentin | 17 | $246 |
| Hydroxyurea | 15 | $223 |
| Levothyroxine Sodium | 20 | $216 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $140 | $185,70812 claims |
| PfizerEliquis | $101 | $38,37160 claims |
| Johnson & JohnsonXarelto | $477 | $15,09013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 157 medical oncology providers in Ohio.
Other medical oncology in Wilmington
- Michael WangBelpre$21.6M
- Kai HeColumbus$10.9M
- Timothy BurnsColumbus$7.2M
- Dwight OwenColumbus$6.8M
- Jennifer SelfridgeCleveland$6.3M
- Moshe OrnsteinCleveland$6.1M
- David CarboneColumbus$5.4M
- Manisha ShahColumbus$4.3M
- Gregory OttersonColumbus$4.1M
- Marcelo BonomiColumbus$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.